CTTC, Spero enter sales agreement for Calmare medical devices

Competitive Technologies, Inc. (OTCQX:CTTC) announced today that it has entered into a sales agreement with Spero Pain Relief Therapy, LLC ("Spero"). Spero, based in St. George, UT, opened its first of 14 planned pain clinics using CTTC's Calmare® Pain Therapy medical device last month. The 13 additional clinics will open over the next two years and will treat those suffering from chronic pain in Utah, Nevada and southern California. Spero has committed to purchase a minimum of 114 Calmare medical devices for the 14 clinics and the devices purchased will produce approximately $3 million in net revenue for CTTC over the two-year period.

"As a physician, it has been very rewarding to observe the extraordinary results from treating a number of my patients suffering from chronic pain with the Calmare Pain Therapy medical device,'' said Dr. Robert Chalmers, Spero's Medical Director. "I am very excited to be offering this non-narcotic treatment to long-suffering patients."

"We are thrilled that Spero has committed to opening these clinics in the Western U.S.," said Johnnie D. Johnson, CTTC's CEO. "Their plan to open additional clinics is a validation of the success Dr. Chalmers has already seen from treating patients with our Calmare device.

"We are convinced that, in addition to successfully treating patients suffering from chemotherapy-induced peripheral neuropathy (CIPN), our Calmare device successfully treats chronic neuropathic pain resulting from cancer, cancer chemotherapy, phantom limb syndrome, failed back surgery, sciatica, spinal stenosis, shingles and other maladies, said Aris Despo, CTTC's Executive Vice President, Business Development. "And it does so non-invasively, without the use of harmful narcotic pain relievers."

Source:

: Competitive Technologies, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers identify two risk factors that indicate higher risk of aggressive prostate cancer